Mortality Prediction in Pulmonary Mycobacterium Kansasii Infection and Human Immunodeficiency Virus
- 1 October 2004
- journal article
- Published by American Thoracic Society in American Journal of Respiratory and Critical Care Medicine
- Vol. 170 (7) , 793-798
- https://doi.org/10.1164/rccm.200402-162oc
Abstract
In the setting of human immunodeficiency virus (HIV) infection, the clinical implications of American Thoracic Society (ATS) diagnostic criteria and the significance of a single positive respiratory culture for Mycobacterium kansasii are unknown. We retrospectively studied HIV-infected patients with pulmonary M. kansasii isolated between 1989 and 2002 at one institution. Of 127 patients, 33% fulfilled ATS disease criteria. Twenty-nine percent received at least three active drugs for at least 3 months, and 53% died. In survival analysis, a lower CD4 count (hazard ratio [HR], 1.6; 95% confidence interval [CI], 1.1-2.3) and positive smear microscopy (HR, 2.8; 95% CI, 1.3-6.1) were associated with mortality, whereas antiretroviral therapy (HR, 0.3; 95% CI, 0.1-0.8) and M. kansasii treatment (HR, 0.4; 95% CI, 0.2-0.9) were associated with survival. ATS criteria did not predict mortality (HR, 0.9; 95% CI, 0.4-1.9). Fifteen patients (12%) apparently had indolent infection, not requiring immediate therapy. They had fewer positive cultures and lower rates of positive smear microscopy and ATS-defined disease. In HIV-infected patients with pulmonary M. kansasii infection, predictors of survival include higher CD4 counts, antiretroviral therapy, negative smear microscopy, and adequate treatment for M. kansasii infection, but not ATS diagnostic criteria. Withholding treatment in HIV-infected patients with respiratory M. kansasii isolates should only be considered with negative smear microscopy, few positive cultures, and mild immunosuppression.Keywords
This publication has 17 references indexed in Scilit:
- Drug‐Drug Interactions in Inmates Treated for Human Immunodeficiency Virus andMycobacterium tuberculosisInfection or Disease: An Institutional Tuberculosis OutbreakClinical Infectious Diseases, 2002
- Epidemiology of human pulmonary infection with mycobacteria nontuberculousClinics in Chest Medicine, 2002
- Nontuberculous MycobacteriaAmerican Journal of Respiratory and Critical Care Medicine, 1999
- Therapeutic Implications of Drug Interactions in the Treatment of Human Immunodeficiency Virus‐Related TuberculosisClinical Infectious Diseases, 1999
- Mycobacterium kansasii and human immunodeficiency virus co-infection in LondonJournal of Infection, 1998
- Cytomegalovirus: The Monster in the Closet?American Journal of Respiratory and Critical Care Medicine, 1997
- Mycobacterium kansasiiDisease in Patients Infected with Human Immunodeficiency VirusClinical Infectious Diseases, 1997
- Mycobacterium kansasii: its presentation, treatment and outcome in HIV infected patients.Journal of Clinical Pathology, 1996
- Mycobacterium kansasii Infections in Patients Positive for Human Immunodeficiency VirusClinical Infectious Diseases, 1991
- Mycobacterium kansasii: A Cause of Treatable Pulmonary Disease Associated with Advanced Human Immunodeficiency Virus (HIV) InfectionAnnals of Internal Medicine, 1991